Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click here to read why REGN is a Buy.

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Biotech giant Regeneron’s (REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post ...

High-dose Eylea, or aflibercept 8 mg, is being jointly developed by Regeneron and Bayer AG. Regeneron shares were down 1.3% Tuesday before being halted in advance of the news.

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application Regeneron Pharmaceuticals, Inc. - GlobeNewswire - Fri Apr 18, 2:00PM CDT ...

A quicker-than-expected U.S. approval for Regeneron Pharmaceuticals' high-dose eye disease drug, Eylea, should help return the blockbuster treatment back to growth in the next few years, Wall ...

Regeneron books full U.S. Eylea sales, and 80% of its Eylea-related revenue comes from the U.S. Blockbuster immunology drug Dupixent so far generates 80% of its sales in the U.S., and Regeneron is ...

Regeneron's Eylea is competing with Roche's Vabysmo in the ophthalmology market, and it could be vulnerable to biosimilars beginning in 2027 and Medicare negotiations in 2028.

Doctors say they’re seeing an unexplained increase in a rare, frightening side effect in patients getting Regeneron Pharmaceuticals Inc.’s top-selling product, the blockbuster eye drug Eylea.